Mohamed M Gad1, Anas M Saad2, Mohammed Faisaluddin3, Mihnea Alexandru Gaman4, Inas A Ruhban5, Khalid A Jazieh2, Muneer J Al-Husseini6, Carlos Roberto Simons-Linares2, M Bassam Sonbol7, Bassam N Estfan8. 1. Cleveland Clinic Foundation, Cleveland, OH, USA; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Cleveland Clinic Foundation, Cleveland, OH, USA. 3. Deccan College of Medical sciences, India. 4. Carol Davila University of Medicine and Pharmacy, Romania. 5. Faculty of Medicine, Damascus University, Syria. 6. Ascension St. John Hospital, Michigan, USA. 7. Department of Hematology and Oncology, Mayo Clinic, AZ, USA. 8. Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: estfanb@ccf.org.
Abstract
BACKGROUND: Cholangiocarcinoma is an aggressive malignancy with few available studies assessing incidence and mortality. In this study, we aim to investigate trends of incidence and mortality in a large nation-wide epidemiologic study. METHODS: We used SEER 18 database to study cholangiocarcinoma cases in the US during 2000-2015. Incidence and mortality rates of cholangiocarcinoma were calculated by race and were expressed by 1,000,000 person-years. Annual percent change (APC) was calculated using joinpoint regression software. RESULTS: We reviewed 16,189 patients with cholangiocarcinoma, of which 64.4% were intrahepatic. Most patients were whites (78.4%), males (51.3%), and older than 65 years (63%). A total of 13,121 patients died of cholangiocarcinoma during the study period. Cholangiocarcinoma incidence and mortality were 11.977 and 10.295 and were both higher among Asians, males, and individuals older than 65 years. Incidence rates have significantly increased over the study period (APC=5.063%, P<.001), while mortality increased significantly over the study period (APC=5.964%, P<.001), but decreased after 2013 (APC=-25.029, P<.001). CONCLUSION: The incidence and mortality of cholangiocarcinoma were increasing in the study period with significant observed disparities based on race and gender.
BACKGROUND:Cholangiocarcinoma is an aggressive malignancy with few available studies assessing incidence and mortality. In this study, we aim to investigate trends of incidence and mortality in a large nation-wide epidemiologic study. METHODS: We used SEER 18 database to study cholangiocarcinoma cases in the US during 2000-2015. Incidence and mortality rates of cholangiocarcinoma were calculated by race and were expressed by 1,000,000 person-years. Annual percent change (APC) was calculated using joinpoint regression software. RESULTS: We reviewed 16,189 patients with cholangiocarcinoma, of which 64.4% were intrahepatic. Most patients were whites (78.4%), males (51.3%), and older than 65 years (63%). A total of 13,121 patientsdied of cholangiocarcinoma during the study period. Cholangiocarcinoma incidence and mortality were 11.977 and 10.295 and were both higher among Asians, males, and individuals older than 65 years. Incidence rates have significantly increased over the study period (APC=5.063%, P<.001), while mortality increased significantly over the study period (APC=5.964%, P<.001), but decreased after 2013 (APC=-25.029, P<.001). CONCLUSION: The incidence and mortality of cholangiocarcinoma were increasing in the study period with significant observed disparities based on race and gender.
Authors: Yi-Te Lee; Amit G Singal; Marie Lauzon; Vatche G Agopian; Michael Luu; Mazen Noureddin; Tsuyoshi Todo; Irene K Kim; Marc L Friedman; Kambiz Kosari; Nicholas N Nissen; Lewis R Roberts; Julie K Heimbach; Gregory J Gores; Ju Dong Yang Journal: Cancer Date: 2022-08-23 Impact factor: 6.921
Authors: Ajacio Bandeira de Mello Brandão; Santiago Rodriguez; Alfeu de Medeiros Fleck; Claudio Augusto Marroni; Mário B Wagner; Alex Hörbe; Matheus V Fernandes; Carlos Ts Cerski; Gabriela Perdomo Coral Journal: World J Clin Oncol Date: 2022-08-24